anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: I. Compare disease control, overall survival, and relapse-free survival in patients with lung metastases secondary to soft tissue sarcoma treated with high-dose doxorubicin and ifosfamide with or without filgrastim (G-CSF) before and after metastasectomy vs metastasectomy alone. II. Determine the safety and morbidity of this regimen in these patients.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to location of metastases (unilateral vs bilateral). Patients are randomized to 1 of 2 treatment arms. Arm I: Patients are assigned to regimen A or B. Regimen A: Patients receive high-dose doxorubicin IV and ifosfamide IV continuously on day 1 and filgrastim (G-CSF) subcutaneously on days 3-13. Regimen B: Patients receive chemotherapy as above without G-CSF. Treatment on both regimens continues every 3 weeks for 3 courses. Patients then undergo radical pulmonary metastasectomy via thoracotomy or sternotomy with wedge resection or lobectomy. Patients with responding disease after metastasectomy receive 2 additional courses on the regimen to which they were originally assigned. Arm II: Patients undergo radical pulmonary metastasectomy as in arm I. Patients are followed every 3 months for 2 years, every 6 months for 2 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 340 patients (170 per treatment arm) will be accrued for this study within approximately 4.5 years.
KEPPRA XR can cause hematologic abnormalities. Hematologic abnormalities occurred in clinical trials and included decreases in white blood cell (WBC), neutrophil, and red blood cell (RBC) counts; decreases in hemoglobin and hematocrit; and increases in eosinophil counts. Cases of agranulocytosis, pancytopenia, and thrombocytopenia have also been reported in the postmarketing setting. A complete blood count is recommended in patients experiencing significant weakness, pyrexia, recurrent infections, or coagulation disorders. 

In controlled trials of immediate-release KEPPRA tablets in patients experiencing partial-onset seizures, minor, but statistically significant, decreases compared to placebo in total mean RBC count (0.03 × 106/mm3), mean hemoglobin (0.09 g/dL), and mean hematocrit (0.38%), were seen in immediate-release KEPPRA-treated patients. 

A total of 3.2% of KEPPRA-treated and 1.8% of placebo-treated patients had at least one possibly significant (≤2.8 × 109/L) decreased WBC, and 2.4% of KEPPRA-treated and 1.4% of placebo-treated patients had at least one possibly significant (≤1.0 × 109/L) decreased neutrophil count. Of the KEPPRA-treated patients with a low neutrophil count, all but one rose towards or to baseline with continued treatment. No patient was discontinued secondary to low neutrophil counts.

In pediatric patients (4 to <16 years of age), statistically significant decreases in WBC and neutrophil counts were seen in patients treated with immediate-release KEPPRA, as compared to placebo. The mean decreases from baseline in the immediate-release KEPPRA group were -0.4 × 109/L and -0.3 × 109/L, respectively, whereas there were small increases in the placebo group. A significant increase in mean relative lymphocyte counts was observed in 1.7% of patients treated with immediate-release KEPPRA compared to a decrease of 4% in patients on placebo.

In the controlled pediatric trial, a possibly clinically significant abnormal low WBC value was observed in 3% of patients treated with immediate-release KEPPRA, compared to no patients on placebo. However, there was no apparent difference between treatment groups with respect to neutrophil count. No patient was discontinued secondary to low WBC or neutrophil counts. 

In the controlled pediatric cognitive and neuropsychological safety study, two subjects (6.1%) in the placebo group and 5 subjects (8.6%) in the immediate-release KEPPRA-treated group had high eosinophil count values that were possibly clinically significant (≥10% or ≥0.7×109/L).
The maturation (differentiation) of dendritic cells has a significant meaning in the initiation of an immune response and in a dendritic cell-based vaccine therapy for various cancer types. However, it remains unknown what functions and roles galectins play in dendritic cells. Thus, it is intended to clarify the functions and roles of galectins and develop a technique of regulating the differentiation of dendritic cells. It is found out that Gal-9 has an activity of inducing the differentiation (maturation) of dendritic cells. It is also found out that Gal-8 similarly has an activity of inducing the differentiation (maturation) of dendritic cells though at a lower level than Gal-9. Dendritic cells having been treated with Gal-9 can stimulate and enhance the production of a Th1 type cytokine as well as the production of IL-10 by T cells. Accordingly, it is possible to develop an antiinflammatory agent, an antiallergic agent, an immune suppressor, an antitumor agent and so on by using the activity of inducing dendritic cell differentiation of Gal-8 or Gal-9. Moreover, it is possible to develop an assay reagent, other drugs, an assay, etc. by using the activity of inducing dendritic cell differentiation as described above.
Kidney stones affect up to 10% of the Canadian population and can lead to pain, hospitalization, lost of time at work, and surgery. Approximately 80% of stones consist of calcium and oxalate, of which both components come from diet and normal bodily processes. Individuals who have high levels of oxalate in their urine have a greater tendency to generate stones. One recommendation is to reduce their intake of oxalate-containing foods, but many healthy foods contain oxalate, and an oxalate-free diet is unpalatable and difficult to achieve. Some patients, despite reducing their oxalate intake, still have high amounts in the urine.

Intestinal metabolism is largely affected by the state and composition of the intestinal bacterial flora, with several metabolic diseases being linked to a disrupted "normal" intestinal flora. The investigators believe that calcium oxalate stone disease as well as high urinary levels of oxalate (hyperoxaluria) are triggered by inefficient oxalate metabolism in the intestine, which is linked to a "disrupted" intestinal bacterial flora that lacks certain key components such as O. formigenes. The long-term purpose of this study is therefore, to determine the effect of replenishing the intestinal flora of patients with that of "normal" controls, thereby re-introducing a balanced environment that will lead to the re-establishment of normal metabolic functions and a decrease in urinary oxalate levels and hopefully lower incidence of stone disease.
[Problem] Fucoxanthin extracted from wakame seaweed ( Undaria pinnatifida ) is effective as an anti-obesity active agent. However, fucoxanthin is contained in mature (adult) brown algae in a small amount, and accordingly, it takes a long time and high cost to obtain fcoxanthin in an amount sufficient for practical use. Further, an anti-obesity active agent showing a stronger effect has been desired. It is, therefore, an object of the present invention to specify a carotenoid exhibiting anti-obesity activity stronger than that of fucoxanthin and to provide an anti-obesity active agent and an anti-obesity method which use the caritenoid. 
     [Means to Solve the Problem] Intensive and extensive studies have been made as to what carotenoid has an anti-obesity activity stronger than that of fucoxanthin and what material should be used in order to economically obtain such a carotenoid. As a result, the answer has been found that the carotenoid is fucoxanthinol. “Sea squirt (ascidian)” is a generic name of marine animals which belong to class Ascidiacea, subphylum Urochordata (Tunicata), phylum Chordata and which live nationwide. As described above, sea squirt (ascidian) is abundantly found as resources. In the present invention, fucoxanthinol is extracted particularly from internal organs and hard skins of sea squirt (ascidian), and it has been revealed that fucoxanthinol exhibits strong anti-obesity activity.
This invention discloses a babu agent ground substance and its preparation method. Water soluble high molecular polymer gelatin, carboxymethylcellulose sodium, polyvinyl pyrrolidon, poly-sodium acrylate, polyvinyl alcohol, white bole, calcium carbonate, zinc oxide, glycerol are used as weight rate to make the ground substance. First, gelatin is watered and heated to dissolve and expand. Then carboxymethylcellulose sodium is watered and heated to dissolve and expand, and then polyvinyl pyrrolidon and polyvinyl alcohol are added. They are equally agitated and be added into gelatin liquor to get I phase liquor. Secondly, poly-sodium acrylate, white bole or calcium carbonate or zinc oxide are dispersed into glycerol, then II phase liquor is got after agitation. Finally, II phase liquor is added into I phase liquor, the babu agent is got after heated and agitated. Its medicine carry is large, medicine compatibility is good, ground material's character is stable, and it doesn't react with main medicine. There is also no stimulus to skin, no anaphylactic response, gas permeation ability is good and preparation technique is simple.
Rapid and sensitive nucleic acid detection is vital in disease diagnosis and therapeutic assessment. Herein, we propose a co-freezing localized CRISPR-Cas12a (CL-Cas12a) strategy for sensitive nucleic acid detection. The CL-Cas12a was obtained through a 15-minute co-freezing process, allowing the Cas12a/crRNA complex and hairpin reporter confined on the AuNPs surface with high load efficiency, for rapid sensing of nucleic acid with superior performance to other localized Cas12a strategies. This CL-Cas12a based platform could quantitatively detect targets down to 98 aM in 30 min with excellent specificity. Furthermore, the CL-Cas12a successful applied to detect human papillomavirus infection and human lung cancer-associated single-nucleotide mutations. We also achieved powerful signal amplification for imaging Survivin mRNA in living cells. These findings highlight the potential of CL-Cas12a as an effective tool for nucleic acid diagnostics and disease monitoring.
The HMP 2.0 Information-Only Control Arm will feature a streamlined version of the website that provides tailored information and content for YBLMT. This follows the design of HMP 1.0 where control arm participants had access to HIV-related Knowledge Center articles of the main intervention without access to the engagement features, interactive forums, or doctor Q\&A. HIV-negative and sero-unknown participants also will be able to request HIV home test kits. The choice of control arm balances equipoise with research study design; in HMP 1.0, control arm participants also experienced a statistically significant intervention benefit.
The invention discloses a circular nucleic acid application-miRNA inhibitor, which relates to the technical field of nucleic acids, wherein miRNA is a single-stranded non-coding RNA with the length of about 20 bases, and the miRNA is used for regulating and controlling biological processes involved in various diseases by combining with mRNA after transcription. The existing miRNA inhibitor is mainly antisense oligonucleotide (ASO), and is a single-stranded DNA molecule reversely complementary to miRNA. However, single-chain forms of ASO are easily degraded in the blood, resulting in low inhibition and bioavailability. The invention provides a method for controlling diseases by inhibiting the expression of miRNA by using artificially synthesized fully closed single-stranded circular nucleic acid (DNA or RNA). Due to its unique circular structure, the fully closed single-stranded circular nucleic acid can resist the degradation of exonuclease in blood and continuously exert the inhibition effect on miRNA. The fully closed single-stranded circular nucleic acid is hopeful to be developed into a new generation of nucleic acid medicaments taking miRNA as a target point.
OBJECTIVES: To assess the impact of the definition of the Global Leadership Initiative in Sarcopenia (GLIS) on mortality in esophageal cancer (EC) patients, postesophagectomy, within a Chinese cohort and to validate the effectiveness of a new GLIS framework in oncology.
METHODS: We performed an observational real-world cohort study in a single center at Daping Hospital of the Army Medical University in China, spanning from December 2014 to July 2022. We used the combined definition of muscle mass and muscle strength in a new GLIS framework for the diagnosis of sarcopenia. Potential covariates were identified through univariate and multivariate analyses. The association between GLIS-defined sarcopenia and mortality was estimated using Kaplan-Meier curves and Cox models. We also conducted stratified analyses to assess the stability of multivariable Cox models.
RESULTS: A total of 520 EC patients were included in the study, with a median follow-up of 48.7 months. A total of 229 EC patients (44.0%) were identified with GLIS-defined sarcopenia. Patients with GLIS-defined sarcopenia had significantly worse overall survival in Kaplan-Meier curves (log-rank P = 0.015). Age; sex; tumor, node, metastasis stage; blood glucose; bleeding volume in operation; and operating time were introduced as covariates in a fully adjusted Cox model. Multivariable-adjusted Cox models revealed that GLIS-defined sarcopenia was an independent prognostic factor for EC patients postesophagectomy (hazard ratio, 1.87, 95% confidence interval, 1.28-2.74, P = 0.001). Stratified analyses confirmed the stability of the relationship between GLIS-defined sarcopenia and mortality in EC patients.
CONCLUSIONS: GLIS-defined sarcopenia is prevalent among Chinese EC patients and is linked to increased mortality risk postesophagectomy. This finding offers compelling evidence and serves as a valuable reference for the establishment of an operational definition of GLIS sarcopenia.
Subjects will be prescribed a 6-week physical therapy regimen consisting of one 45 minute in office visit per week, and home exercises performed daily. The in-office visits with a physical therapy provider will consist of the application of manual therapy, particularly high-velocity, low amplitude thrust mobilization in the anterior/posterior direction of the lumbar spine. In office visits will also include supervised repeated motion of the lumbar spine into extension (McKenzie therapy, 3 sets of 10 repetitions, in prone and standing positions) Patients will be instructed to complete these repeated extension exercises at home daily for the 6 week period.
BACKGROUND: Meningiomas are the most common primary intracranial tumors in adults. Although benign in a majority of cases, they have a variable clinical course and may recur even after a thorough surgical resection. Ki-67, a nuclear protein involved in cell cycle regulation, has been widely studied as a marker of cellular proliferation in various cancers. However, the prognostic significance of Ki-67 in meningiomas remains controversial. Here, we investigate the Ki-67 index, as a predictive marker of meningioma recurrence following surgical resection and compare it to established prognostic markers such as WHO grade and degree of resection.
METHODS: The medical records of 451 patients with previously untreated cranial meningiomas who underwent resections from January 2011 to January 2021 at North Shore University Hospital (NSUH) were reviewed. Collected data included WHO grade, Ki-67 proliferative index, degree of resection - gross (GTR) vs subtotal (STR) - as judged by the surgeon, tumor location, and meningioma recurrence. This study was approved by the NSUH Institutional Review Board IRB 21-1107.
RESULTS: There were 290 patients with grade I, 154 with grade II, and 7 with grade III meningiomas. The average post-resection follow-up period was 4 years, and 82 tumors (18 %) recurred. Higher WHO grades were associated with higher rates of recurrence, with rates of 11.4 %, 27.9 %, and 71.4 % for grades 1, 2, and 3, respectively, and subtotal resection corresponded to a higher rate of recurrence than total resection (34.3 % and 13.4 %, respectively). Higher WHO grades also correlated with higher Ki-67 scores (2.59, 10.01, and 20.71) for grades 1, 2, and 3, respectively. A multivariate logistic regression model identified Ki-67 and degree of resection as independent predictive variables for meningioma recurrence, with Ki-67 specifically predicting recurrence in the WHO grade II subset when analyzed separately for WHO grades I and II.
CONCLUSION: Our 10-year retrospective study suggests that the Ki-67 index is an important predictive marker for recurrence of intracranial meningiomas following surgical resection, particularly among patients with WHO grade II tumors. Our findings add to a growing body of data that support inclusion of Ki-67 index in the WHO grading criteria for patients with meningiomas.
PROBLEM TO BE SOLVED: To obtain a solid pharmaceutical composition for vaginal use, enabling the improvement of the retention at the administered site and capable of exhibiting the effect for a long time when a treating agent is administered by using a specifically treated biologically adhesive polymer. SOLUTION: One kind or more of mucosa adhesive polymers dispersed in a pharmaceutical permissible support is used together with a treating agent. The ratio of the mucosa adhesive polymer in the composition is 0.5-90wt.%. As the mucosa adhesive polymer, polycarbophil, a polyacrylic acid derivative, its salt, a vinyl carboxylic acid polymer, its copolymer, its salt, etc., is preferable. As the treating agent, an antifungal agent an anti-protozoal agent, a disinfectant, a hormone preparation, an antibiotic, etc., is preferable. The composition is used in a form of a vaginal tablet or a suppository using a gelatin soft capsule, etc. As the support, powder, a solid, a liquid of a semisolid state or an anhydrous liquid, which is commonly used in a drug or a cosmetic, is used.
Naja atra bites often result in immediate and severe illness. The venom of N. atra contains a complex mixture of toxins that can cause significant damage to the patient's skin tissue. If left untreated, this condition can progress to localized necrosis, potentially resulting in impairment or even amputation in severe cases. Despite the known effects of the venom, the exact mechanisms underlying this tissue necrosis are not fully understood. This study aimed to investigate the protein components responsible for tissue necrosis induced by N. atra venom at both the organism-wide and molecular levels. To achieve this, venom was injected into Bama miniature pigs to cause ulcers, and exudate samples were collected at various time points after injection. Label-free proteomics analysis identified 1119, 1016, 938, 864, and 855 proteins in the exudate at 6, 12, 24, 36, and 48 h post-injection, respectively. Further analysis revealed 431 differentially expressed proteins, with S100A8, MMP-2, MIF, and IDH2 identified as proteins associated with local tissue necrosis. In this study, we established a Bama miniature pig model for N. atra venom injection and performed proteomic analysis of the wound exudate, which provides important insights into the molecular pathology of snakebite-induced tissue necrosis and potential theoretical bases for clinical treatment. Proteomic data from this study can be accessed through ProteomeXchange using the identifier PXD052498.
<P>PROBLEM TO BE SOLVED: To provide a system, a device, a method, and a program for health management capable of presenting efficient and appropriate advice according to a user condition.  <P>SOLUTION: A medical examination interview presenting module 52 periodically presents a medical examination interview to a user terminal 1. An advice selection module 51 selects one of a plurality of advice algorithm registered in an algorithm database 57 on the basis of physiological data, a medical examination interview answer, and a personal set value to present it as an automatic advice to the user terminal 1. The advice selection module 51 asks a doctor terminal 2 for determination if it cannot presents the automatic advice. The doctor terminal 2 presents individual advice to the user terminal 1 via a personal bulletin board of an individual advice module 54. An advice construction module 53 extracts a Q&A history from a Q&A history database 59 to create an advice algorithm.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Heart failure with preserved ejection fraction (HFpEF) has a high prevalence, affecting more than 50% of patients with heart failure. HFpEF is associated with multiple comorbidities, and obesity is one of the most common. A distinct phenotype has been proposed for obese patients with HFpEF. Recent data show the beneficial role of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight loss in diabetic and non-diabetic patients with obesity or overweight when given as adjunctive therapy to diet and exercise. The mechanisms of action are related to paracrine and endocrine signalling pathways within the gastrointestinal tract, pancreas, and central nervous system that delay gastric emptying, decrease appetite, augment pancreatic beta-cell insulin secretion, and suppress pancreatic glucagon release. These drugs are therefore potentially indicated for treatment of patients with HFpEF and obesity or overweight. Efficacy and safety need to be shown by clinical trials with a first one, Semaglutide Treatment Effect in People with obesity and heart failure with preserved ejection fraction (STEP HFpEF), recently concluded. The aim of the present review is to provide the pathophysiological and pharmacological rationale for GLP-1 RA administration to obese patients with HFpEF.
[Problem] Conventionally, the type of blood sugar constitution of a user cannot be easily known. [Solution] The type of blood sugar constitution can be easily known via a blood sugar constitution assessment device comprising a storage unit, an output unit, a reception unit, a processing unit, and an information output unit. The storage unit stores one or more pieces of question information including a question pertaining to lifestyle habits, the one or more pieces of question information being used to determine the type of blood sugar constitution. The output unit outputs the one or more pieces of question information. The reception unit receives, from a user, one or more pieces of response information to each of the pieces of question information. The processing unit uses the one or more pieces of response information received by the reception unit to determine the type of blood sugar constitution of the user. The information output unit outputs output information pertaining to the type of blood sugar constitution.
Primary congenital glaucoma etiology still remains obscure . originally barkan , and later Worst , proposed that a membrane covered the anterior chamber angle and blocked aqueous outflow , but the presence of that membrane has not been established histopathologically to date . Now most authors believe that the site of obstruction is the trabecular meshwork rather than an overlying membrane . Maldevelopment of the anterior segment is present in all forms of congenital glaucoma . this maldevelopment may involve the trabecular meshwork alone or the trabecular meshwork in combination with the iris or cornea or both. In approcimately 50% of patients , isolated trabeculodysgensis is the only developmental ocular anomaly found .This is the classic defect found in primary congenital glaucoma .These eyes have no developmental anomalies of iris or cornea present except abnormal insertion of the iris into the angle